# Advanced Development and Clinical Evaluation of an Entamoeba histolytica Vaccine

> **NIH NIH N01** · ACCESS TO ADVANCED HEALTH INSTITUTE · 2021 · $2,853,145

## Abstract

To support advanced development of a synthetic intranasal Entamoeba histolytica vaccine containing adjuvant. This contract may support formulation and manufacture of the individual vaccine components, as well as stability testing, nonclinical immunogenicity and efficacy testing in nonhuman primates, IND enabling GLP repeated dose toxicology, submission of an IND and eventual clinical evaluation.

## Key facts

- **NIH application ID:** 10359666
- **Project number:** 272201800025C-P00004-9999-1
- **Recipient organization:** ACCESS TO ADVANCED HEALTH INSTITUTE
- **Principal Investigator:** CHRISTOPHER FOX
- **Activity code:** N01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $2,853,145
- **Award type:** —
- **Project period:** 2018-09-21 → 2022-09-17

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10359666

## Citation

> US National Institutes of Health, RePORTER application 10359666, Advanced Development and Clinical Evaluation of an Entamoeba histolytica Vaccine (272201800025C-P00004-9999-1). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10359666. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*